ENGN
enGene Holdings Inc.8.38
-0.05-0.59%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
560.39MP/E (TTM)
-Basic EPS (TTM)
-1.90Dividend Yield
0%Recent Filings
8-K
New $100M ATM sales pact
enGene Holdings entered a $100 million at-the-market sales agreement with Leerink Partners on March 9, 2026, after terminating its prior Jefferies pact effective March 6 with no shares sold or penalties. Leerink earns up to 3% commission on proceeds from Nasdaq sales, excluding Canada. No sales obligated. Fresh capital channel opens smoothly.
10-Q
Q1 FY2026 results
enGene's Q1 FY2026 operating loss widened 17% y/y to $31.2M on steeper R&D ($22.3M, up 11%) and G&A ($8.9M, up 34%), driven by personnel costs and clinical operations for detalimogene's pivotal LEGEND cohort. Net loss hit $29.8M ($0.44/share) versus $24.6M ($0.48/share) last year, with the gap to operating loss reflecting $0.7M interest expense, $0.5M debt extinguishment, offset by $2.7M interest income. Cash burn eased to $28.9M operating outflow, bolstered by $140M net public offering and $25M Second Amended Term Loan (matures 2030 at ~9.25-10.25%, $100M more available on milestones). Balance sheet strengthened to $312.5M in cash/marketables against $24.9M net debt. Cash lasts 12+ months. Yet clinical trial delays loom large.
8-K
Q1 loss widens, cash strong
8-K
enGene expands debt facility to $125M
enGene Holdings secured a second amendment to its loan agreement with Hercules Capital on January 20, 2026, boosting the term loan facility from $50 million to up to $125 million across five milestone-tied tranches, starting with a $25 million advance to refinance prior loans. Maturity extends to January 1, 2030, with interest at the greater of prime +2.25% (capped at 10.25%) or 9.25%, plus a 5.95% end-of-term fee; lenders received 40,850 warrants at $9.18 exercise price. Funds milestone access ties to clinical, approval, and commercial successes—yet draws hinge on hitting those marks.
8-K
Expands debt to $125M
enGene Holdings expanded its debt facility with Hercules Capital to $125 million via a second amendment on January 20, 2026. $25 million funded immediately refinances prior debt; up to $100 million more hinges on milestones, maturing January 1, 2030. Non-dilutive cash bolsters the balance sheet for detalimogene's BLA filing in H2 2026. Additional proceeds aren't guaranteed.
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CGON
CG Oncology, Inc.
37.85-1.90
EDIT
Editas Medicine, Inc.
2.51+0.07
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
ENZN
Enzon Pharmaceuticals, Inc.
0.05+0.00
IMA
ImageneBio, Inc.
6.25+0.08
NGNE
Neurogene Inc.
19.53-0.73
PEPG
PepGen Inc.
5.52+0.05
TVGN
Tevogen Bio Holdings Inc.
0.38-0.01
URGN
UroGen Pharma Ltd.
23.47+0.62